PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32619930-0	2020	Inhibition of PIM1 kinase attenuates bleomycin-induced pulmonary fibrosis in mice by modulating the ZEB1/E-cadherin pathway in alveolar epithelial cells.	Bleomycin	37-46	cadherin 1	Mus musculus	105-115	
27279470-8	2016	The protein levels of Vimentin and phospho-SMAD2 were upregulated, whereas the level of E-cadherin was downregulated in the MCMV+bleomycin group,.	Bleomycin	129-138	cadherin 1	Mus musculus	88-98	
30136377-9	2019	Bleomycin-induced lung fibrosis was associated with increased alpha smooth muscle actin (alpha-SMA) and decreased E-cadherin expression (P < 0.01).	Bleomycin	0-9	cadherin 1	Mus musculus	114-124	
31085231-3	2019	We found that bleomycin-induced lung fibrosis was associated with increased transforming growth factor (TGF)-beta1, alpha-smooth muscle actin (alpha-SMA) and decreased E-cadherin expression in lung tissues, indicating EMT formation.	Bleomycin	14-23	cadherin 1	Mus musculus	168-178	
21596473-8	2011	When the ATII-like cells were exposed to either bleomycin or a TGF(b1)-EGF cocktail, they underwent phenotypic changes including acquisition of a mesenchymal/fibroblastic morphology, upregulation of mesenchymal markers (Col1, Vim, a-Sma, and S100A4), and downregulation of surfactant proteins and E-cadherin.	Bleomycin	48-57	cadherin 1	Mus musculus	297-307	
27249616-5	2016	Moreover, resveratrol also inhibited the BLM-induced EMT-associated molecular events, such as reduced E-cadherin and elevated Collagen I and alpha-SMA.	Bleomycin	41-44	cadherin 1	Mus musculus	102-112	
23239155-10	2013	The lungs of bleomycin-treated SOPten(Delta/Delta) mice showed increased pAkt, pS6K, Snail, and matrix metalloproteinase expressions and decreased claudin-4, E-cadherin, and laminin-beta1 expressions.	Bleomycin	13-22	cadherin 1	Mus musculus	158-168	
26859835-4	2016	In lung tissues of bleomycin-treated mice, HSP27 was strongly upregulated and substantially co-localized with alpha-SMA, OPN and type I collagen but not with proSP-C (a marker of type II alveolar epithelial cells), E-cadherin (a marker of epithelial cells) or F4/80 (a marker of macrophages).	Bleomycin	19-28	cadherin 1	Mus musculus	215-225	
23688655-6	2013	gammaH2AX immunostaining of the bleomycin-treated lungs revealed double-strand breaks (DSBs), largely within E-cadherin-positive, beta4-integirn-positive alveolar epithelial cells.	Bleomycin	32-41	cadherin 1	Mus musculus	109-119	
12759241-6	2003	E-cadherin ectodomain was shed into the bronchoalveolar lavage fluid of bleomycin-injured wild-type mice, but was not shed in matrilysin-null mice.	Bleomycin	72-81	cadherin 1	Mus musculus	0-10	
34681813-7	2021	Utilization of an in vivo lung injury model by treating bleomycin on mice followed by ATL treatment to demonstrate the therapeutic effectiveness, such as, less collagen deposition and lower E-cadherin expression.	Bleomycin	56-65	cadherin 1	Mus musculus	190-200